Abstract
We herein demonstrate three patients diagnosed with early hepatocellular carcinoma (HCC) during follow-up for Fontan-associated liver disease (FALD). Case 1: Twenty-one years after undergoing the Fontan procedure, a 26-year-old female was diagnosed with FALD. At the initial consultation, her serum alpha-fetoprotein (AFP) levels were markedly elevated, and dynamic enhanced computed tomography (CT) revealed HCC measuring 40 mm in diameter. She underwent partial hepatectomy. Ten months later, she underwent conventional transcatheter arterial chemoembolization (cTACE) for recurrent HCC near the resected hepatic stump as a curative treatment. Case 2: Twenty-one years after undergoing the Fontan procedure, a 25-year-old male was diagnosed with FALD and underwent HCC surveillance every 6 months. Thirteen months after the initial consultation, dynamic enhanced CT revealed HCC measuring 10 mm in diameter. He received cTACE as a curative treatment. Case 3. Twenty-eight years after undergoing the Fontan procedure, a 37-year-old male was diagnosed with FALD and underwent HCC surveillance every 3 months. Fourteen months later, abdominal ultrasonography (US) revealed HCC measuring 13 mm in diameter. He received radiofrequency ablation. These cases showed that HCC surveillance using abdominal US and AFP measurements in patients with FALD enables the detection of HCC and increases the chance of a cure.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
d’Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation. 2007;116:I157–64.
Khairy P, Fernandes SM, Mayer JE, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85–92.
Stanton RE, Lurie PR, Lindesmith GG, et al. The Fontan procedure for tricuspid atresia. Circulation. 1981;64:II140–6.
Ghaferi AA, Hutchins GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg. 2005;129:1348–52.
Rodriguez De Santiago E, Téllez L, Guerrero A, et al. Hepatocellular carcinoma after Fontan surgery: a systematic review. Hepatol Res. 2021;51:116–34.
Egbe AC, Poterucha JT, Warnes CA, et al. Hepatocellular carcinoma after Fontan operation: multicenter case series. Circulation. 2018;138:746–8.
Endo M, Soroida Y, Sato M, et al. Ultrasound evaluation of liver stiffness: accuracy of ultrasound imaging for the prediction of liver cirrhosis as evaluated using a liver stiffness measurement. J Med Dent Sci. 2017;64:27–34.
Shimizu H, Endo S, Natsugoe S, et al. Thoracic and cardiovascular surgery in Japan in 2016: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2019;67:377–411.
Akintoye E, Miranda WR, Veldtman GR, et al. National trends in Fontan operation and in-hospital outcomes in the USA. Heart. 2019;105:708–14.
Kudo M, Izumi N, Kokudo N, et al. Report of the 21st nationwide follow-up survey of primary liver cancer in Japan (2010–2011). Hepatol Res. 2021;51:355–405.
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology. 2018;68:723–50.
Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003;39:1076–84.
Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med. 2001;20:99–104.
Gupta S, Bent S, Kohwles J. Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003;139:46–50.
Tayob N, Lok ASF, Do KA, et al. Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clin Gastroenterol Hepatol. 2016;14(469–75): e2.
Rosenbaum J, Vrazas J, Lane GK, et al. Cardiac cirrhosis and hepatocellular carcinoma in a 13-year-old treated with doxorubicin microbead transarterial chemoembolization. J Paediatr Child Health. 2012;48:E140–3.
Yamada K, Shinmoto H, Kawamura Y, et al. Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis. Pediatr Int. 2015;57:766–70.
Saliba T, Dorkhom S, O’Reilly EM, et al. Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol. 2010;22:889–91.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109–13.
Acknowledgements
The authors would like to thank Dr. Kenji Nishida for the pathological diagnosis.
Author information
Authors and Affiliations
Contributions
All authors made substantial contributions to the conception of the work. HO drafted the original manuscript. NT and other authors substantially contributed to the revision of the manuscript drafts. All authors have approved the submitted version of the manuscript and agreed to be accountable for any part of the work.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest in association with the present study.
Human rights
All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed consent
Informed consent was obtained from all the patients for publication of this case report and any accompanying images.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Onishi, H., Toh, N., Akagi, T. et al. Detection of hepatocellular carcinoma during Fontan-associated liver disease follow-up: a report of three cases. Clin J Gastroenterol 17, 148–154 (2024). https://doi.org/10.1007/s12328-023-01892-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-023-01892-w